About us
A biotechnological company focused on developing new drugs from CIMA (Center of Applied Medical Research) of the University of Navarra.
PIPELINE
An extensive pipeline for several diseases in Hepatology, Gene therapy, Oncology and Cardiovascular were developed so far. Three products are already in clinical phase. It is expected a new product reaching clinical trials every year.
RESEARCH AND PRODUCTS
The goal of the company is to develop the patented products to clinical proof-of-concept and to forge partnerships with other biopharmaceutical companies in order to complete clinical development and commercial launch.
INVESTORS
Some of the most important companies and financials Institution in Spain trust in the economic potential of Digna Biotech and invest in our company.
NEWS
|
02-01-2012 Topical formulation of peptide 144 transforming growth factor (TGF) beta 1 inhibitor |
|
14-11-2011 Digna Biotech regains all rights to Disitertide (P144) to treat skin conditions |
Events
Newsletter
Would you like to receive updates about Digna Biotech? Sign up for our newsletter.
© Digna Biotech · Legal information · Company associated to ASEBIO
